Detalhe da pesquisa
1.
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.
Cell
; 162(6): 1271-85, 2015 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26359985
2.
High-Speed Live-Cell Interferometry: A New Method for Quantifying Tumor Drug Resistance and Heterogeneity.
Anal Chem
; 90(5): 3299-3306, 2018 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29381859
3.
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
Nature
; 480(7377): 387-90, 2011 Nov 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-22113612
4.
Vemurafenib resistance reprograms melanoma cells towards glutamine dependence.
J Transl Med
; 13: 210, 2015 Jul 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-26139106
5.
Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma.
Cancer Discov
; 13(4): 880-909, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36700848
6.
Multi-organ landscape of therapy-resistant melanoma.
Nat Med
; 29(5): 1123-1134, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37106167
7.
Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth.
Cancer
; 118(3): 750-60, 2012 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21751201
8.
Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance.
Cancer Discov
; 12(8): 1942-1959, 2022 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35638972
9.
Targeted profiling of human extrachromosomal DNA by CRISPR-CATCH.
Nat Genet
; 54(11): 1746-1754, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36253572
10.
Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges.
Cancer Discov
; 12(4): 1046-1069, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34930786
11.
SPRED1 deletion confers resistance to MAPK inhibition in melanoma.
J Exp Med
; 218(3)2021 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33306107
12.
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.
Cancer Cell
; 39(10): 1375-1387.e6, 2021 10 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34416167
13.
Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity.
Cancer Discov
; 11(3): 714-735, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33318037
14.
Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma.
Cancer Discov
; 8(1): 74-93, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28923912
15.
mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours.
Curr Med Chem
; 14(13): 1381-7, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17584050
16.
Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.
Cancer Discov
; 7(11): 1248-1265, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28864476
17.
JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma.
Cell Discov
; 2: 16028, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27648299
18.
Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.
Cancer Cell
; 27(2): 240-56, 2015 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-25600339
19.
Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models.
PLoS One
; 9(3): e90795, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24599309
20.
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.
Cancer Discov
; 4(1): 69-79, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24265152